While targeting tumor-associated B7H3 as the next generation of immune checkpoint therapy is actively investigated in the form of monoclonal antibodies, small molecules and chimeric antigen receptor T cells, it is important to recognize the potential for occurrence of this phenomena. This evidence concerns the gene CD276 and neoplasm.